- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Imaging technique proves useful for ovarian cancer
A molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer, according to a study published in the Journal of Nuclear Medicine.
A molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer, according to a study published in the Journal of Nuclear Medicine. Cisplatin is often effective against ovarian cancer when first given, but tumors can become resistant and start growing again.
The study showed F-18 fluorothymidine (F-FLT) PET was able to predict early response to everolimus (a mammalian target of rapamycin inhibitor) in cisplatin-resistant ovarian cancer in mice. The technique should be considered for therapeutic assessment in humans, according to the researchers.
No significant change in tumor F-FLT uptake was observed in the controls. In the everolimus-treated mice, F-FLT standard uptake value decreased by 33% on the second day of treatment and by 66% on the seventh day. There were also changes in tumor volume.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
